Agilent Technologies (NYSE:A) extended its winning stock streak to six consecutive trading days following a strong second-quarter fiscal 2026 earnings report. The company posted net income of $339 million, representing a 58% increase from $215 million in the same period last year, while net revenues grew by 10% to reach $1.835 billion, surpassing analyst expectations which ranged between $1.79 billion and $1.82 billion. Driven by this solid performance, investors also raised their growth outlook for the full fiscal year.
Guidance for the upcoming third quarter remains positive, with expected revenues projected between $1.83 billion and $1.85 billion, implying a 5% to 6% growth rate compared to the $1.74 billion reported in the same period last year. Beyond financial results, Agilent announced a cash dividend of 25.5 cents per share for shareholders of record on June 30, 2026, with payment scheduled for July 22. Additionally, the firm introduced a new product called OpenLab Sync, a lab execution system designed to digitally connect scientific workflows from design through bench-level execution. This new system aims to enhance consistency and data integrity in regulated environments by providing guided digital workflows that reduce procedural ambiguity and improve traceability across teams and locations.
📈 Agilent extends winning streak with 58% net income surge.
💰 Revenue beats expectations at $1.835 billion with upbeat Q3 outlook.
💵 Company announces 25.5 cent dividend payable July 22, 2026.
🧪 New OpenLab Sync system enhances digital lab workflow integrity.
📉 Report suggests AI stocks may offer greater upside potential.
📈 Agilent Technologies extended its winning streak to a 6th consecutive day following strong earnings performance.
💰 Net income surged 58% year-over-year to $339 million, driven by robust fiscal year 2026 second-quarter results.
📊 Net revenues increased 10% to $1.835 billion, surpassing analyst expectations of $1.79 billion to $1.82 billion.
🔮 The company provided an upbeat outlook for the third quarter with expected revenues between $1.83 billion and $1.85 billion.
💵 Agilent announced a cash dividend distribution of 25.5 cents per share to shareholders on record as of June 30, 2026.
📅 Dividend payments are scheduled to be made on July 22, 2026.
🧪 Agilent introduced a new lab execution system called OpenLab Sync to digitally connect scientific workflows.
🔒 The new system aims to improve data integrity and audit readiness in regulated environments through guided digital workflows.
📉 The article suggests that while Agilent is a potential investment, certain AI stocks may offer greater upside potential.
📰 Readers are directed to a free report on undervalued AI stocks benefiting from tariff policies and onshoring trends.
Bullish Signals
- Agilent extended winning streak to 6th consecutive day.
- Net income grew 58% to $339 million.
- Revenues rose 10% to $1.835 billion, beating expectations.
- Q3 revenue outlook implies 5-6% growth from last year.
- Agilent announced 25.5 cent dividend per share for July 22.
- New OpenLab Sync system connects scientific workflows digitally.
Risk Factors
- Agilent acknowledged but offers less upside than other AI stocks.
- Agilent lacks specific growth catalysts like Trump-era tariff benefits.
Bullish Signals
- Agilent Technologies extended its winning streak to a 6th consecutive day, driven by strong earnings performance in the second quarter of fiscal year 2026.
- The company grew its net income by 58 percent to $339 million from $215 million in the same period last year.
- Net revenues increased by 10 percent to $1.835 billion, beating earlier expectations of $1.79 billion to $1.82 billion.
- Management posted an upbeat outlook for the third quarter with revenues expected between $1.83 billion and $1.85 billion, implying growth of 5 to 6 percent from last year's $1.74 billion.
- Agilent announced a cash dividend distribution of 25.5 cents per share to shareholders on record as of June 30, 2026, with payments scheduled for July 22.
- The company introduced the new OpenLab Sync lab execution system to digitally connect scientific workflows and improve traceability across teams and locations.
Risk Factors
- The article explicitly states that while Agilent is acknowledged as an investment, certain AI stocks offer greater upside potential and carry less downside risk.
- The text suggests investors should look elsewhere for extremely undervalued AI stocks that benefit from Trump-era tariffs and the onshoring trend, implying Agilent may lack these specific growth catalysts.
Agilent Technologies Inc. (NYSE:A) extended its winning streak for six consecutive days following a strong second-quarter fiscal 2026 earnings report, with net income surging 58% to $339 million from $215 million a year ago. Net revenues rose 10% to $1.835 billion, surpassing analyst expectations of $1.79 billion to $1.82 billion, as investors responded positively to the company's performance and raised its full-year growth outlook. The company provided an upbeat forecast for the third quarter, projecting revenues between $1.83 billion and $1.85 billion, representing a 5% to 6% increase from the prior year period. Additionally, Agilent announced a cash dividend of 25.5 cents per share for shareholders of record on June 30, 2026, with payments scheduled for July 22. On the product front, the firm introduced OpenLab Sync, a new lab execution system designed to digitally connect scientific workflows from method design through bench-level execution, aiming to enhance data integrity and audit readiness in regulated environments.
📈 Agilent stock rose for the sixth day after beating earnings and revenue expectations.
💰 Net income jumped 58% to $339 million with strong Q2 fiscal 2026 results.
🧪 New OpenLab Sync software connects scientific workflows to improve data integrity.
📈 Agilent Technologies extended its winning streak to a sixth consecutive trading day following strong earnings results.
💰 Net income surged 58% year-over-year to $339 million, driven by robust second-quarter fiscal 2026 performance.
📊 Net revenues grew 10% to $1.835 billion, surpassing analyst expectations of $1.79 billion to $1.82 billion.
🔮 The company provided an upbeat outlook for the third quarter with revenue guidance between $1.83 billion and $1.85 billion.
💵 Agilent announced a cash dividend of 25.5 cents per share, payable on July 22 to shareholders of record by June 30.
🧪 The firm launched OpenLab Sync, a new lab execution system designed to digitally connect scientific workflows from design to bench.
🛡️ The new software aims to enhance data integrity and audit readiness in regulated environments through guided digital workflows.
📉 Despite strong earnings, analyst Baird recently cut its price target for Agilent to $155.
🤖 The article includes a promotional note suggesting AI stocks may offer higher returns than Agilent over the short term.
📰 This news was published on May 28, 2026, as part of a broader list of stocks racking up gains.
Bullish Signals
- Agilent extended winning streak to 6th consecutive day.
- Net income surged 58% to $339 million.
- Revenues rose 10% to $1.835 billion, beating expectations.
- Q3 outlook implies 5-6% revenue growth from last year.
- Agilent announced 25.5 cent dividend per share for July.
- New OpenLab Sync system improves lab workflow traceability.
Risk Factors
- Emerald Growth downgrades Agilent due to margin compression.
- Agilent offers lower returns than AI stocks over short term.
- Baird cuts Agilent price target to $155, signaling downside.
Bullish Signals
- Agilent Technologies extended its winning streak to a 6th consecutive day, driven by strong earnings performance in the second quarter of fiscal year 2026.
- Net income grew by 58% to $339 million from $215 million in the same period last year, demonstrating significant profitability growth.
- Net revenues increased by 10% to $1.835 billion year-on-year, beating earlier expectations of $1.79 billion to $1.82 billion.
- The company posted an upbeat outlook for the third quarter with expected revenues between $1.83 billion and $1.85 billion, implying growth of 5% to 6% from last year's $1.74 billion.
- Agilent announced a cash dividend distribution of 25.5 cents per share to shareholders on record as of June 30, 2026, with payments scheduled for July 22.
- The company introduced a new lab execution system called OpenLab Sync, which digitally connects scientific workflows and improves traceability across teams and locations.
Risk Factors
- Agilent Technologies Inc. (NYSE:A) is explicitly downgraded by Emerald Growth Equity Strategy due to compression in the margin, indicating deteriorating profitability despite reported earnings growth.
- The article suggests that Agilent holds less promise than AI stocks for delivering higher returns within a shorter time frame, positioning it as a relatively inferior investment opportunity compared to emerging technology sectors.
- Analyst Baird has cut its price target on Agilent Technologies Inc. (NYSE:A) to $155, signaling reduced valuation expectations and potential downside risk from current market prices.
Agilent Technologies (NYSE: A) shares surged nearly 17% on Thursday following the release of its fiscal second-quarter earnings report, which significantly exceeded analyst expectations. The company reported revenue of $1.83 billion, representing a 10% year-over-year increase, while non-GAAP net income rose 14% to $423 million, or $1.49 per share. These results beat the consensus estimates of $1.8 billion in revenue and $1.41 per share in adjusted net income, driven by growth across all three reporting units: Applied Markets Group (up 14%), Life Sciences and Diagnostics (up 12%), and CrossLab (up 6%).
In response to the strong quarterly performance, management raised its full-year 2026 revenue guidance range to $7.39 billion to $7.49 billion from a previous outlook of $7.35 billion to $7.45 billion. Additionally, the company increased its adjusted net income projection for the year to between $6.00 and $6.10 per share, up from the prior estimate of $5.90 to $6.04 per share. The broad-based growth across segments and the upward revision of guidance have bolstered investor confidence in Agilent's future trajectory.
📈 Agilent shares jumped 17% after beating Q2 earnings estimates.
💰 Revenue rose 10% to $1.83B with all units growing double-digits.
🚀 Full-year guidance upgraded for revenue and adjusted net income per share.
📈 Agilent Technologies shares surged nearly 17% on Thursday following its quarterly earnings report.
💰 The company reported Q2 fiscal 2026 revenue of $1.83 billion, representing a 10% year-over-year increase.
📊 Non-GAAP net income rose 14% to $423 million, or $1.49 per share, beating analyst estimates.
🔬 All three reporting units delivered double-digit revenue growth, led by the Applied Markets Group at 14%.
🧬 The life sciences and diagnostics segment grew 12%, while CrossLab increased by 6% to $759 million.
📈 Management raised its full-year 2026 revenue guidance range to $7.39 billion–$7.49 billion.
💵 Adjusted net income projection was upgraded to $6.00–$6.10 per share from the previous estimate of $5.90–$6.04.
📉 Agilent beat consensus estimates for both revenue ($1.8B) and non-GAAP EPS ($1.41).
🚀 The Motley Fool Stock Advisor team did not include Agilent in their latest list of 10 best stocks to buy now.
📊 Stock Advisor highlights historical returns with Netflix and Nvidia as examples of past top picks.
⚠️ Investors are encouraged to consider the company's strong performance before making purchase decisions.
🤝 Eric Volkman and The Motley Fool disclose they hold no positions in the mentioned stocks.
Bullish Signals
- Agilent shares surged 17% on strong Q2 earnings.
- Fiscal Q2 2026 revenue hit $1.83 billion, up 10%.
- Non-GAAP net income jumped 14% to $423 million.
- All units grew; Applied Markets led with 14% rise.
- Life sciences segment boosted 12% to $732 million.
- Full-year 2026 revenue guidance raised to $7.39-$7.49 billion.
- Adjusted EPS projection increased to $6-$6.10 per share.
Risk Factors
- Agilent excluded from Motley Fool top 10.
- Strategy may overlook Agilent Technologies.
Bullish Signals
- Agilent Technologies shares surged nearly 17% on Thursday following a strong quarterly earnings report.
- The company reported fiscal second quarter 2026 revenue of $1.83 billion, representing a 10% year-over-year increase.
- Non-GAAP net income jumped 14% to $423 million, or $1.49 per share, significantly beating analyst estimates of $1.41 per share.
- All three reporting units delivered revenue growth, with the Applied Markets Group leading at a 14% rise to $344 million.
- The life sciences and diagnostics segment also showed robust performance with a 12% boost to $732 million.
- Management raised full-year 2026 revenue guidance to a range of $7.39 billion to $7.49 billion, expanding the bottom end.
- Adjusted net income projection was dramatically increased to $6 to $6.10 per share from the previous estimate of $5.90 to $6.04.
Risk Factors
- The article explicitly states that Agilent Technologies was not included in The Motley Fool Stock Advisor's list of 10 best stocks to buy now, suggesting it may be overlooked by this specific investment strategy.
Snowflake shares surged nearly 37% in premarket trading following first-quarter results that beat analyst expectations, with adjusted earnings of 39 cents per share and revenue of $1.39 billion against estimates of 32 cents and $1.32 billion respectively. The company also announced a significant commitment to spend $6 billion on Amazon Web Services over the next five years. This positive momentum extended to its software peers, with DataDog rising 6% and ServiceNow gaining more than 5.5%.
Other notable movers included Best Buy, which climbed almost 8% after beating earnings and revenue estimates with comparable sales up 2%, and Kohl's, which rose nearly 11% after reporting a narrower-than-expected first-quarter loss of 13 cents per share compared to an anticipated loss of 19 cents. Dollar Tree also saw significant gains, surging more than 11% after adjusted earnings of $1.74 per share exceeded the expected $1.53, alongside strong revenue and updated guidance.
In contrast, Hormel Foods shares popped 10% on fiscal second-quarter adjusted earnings of 40 cents versus an expected 35 cents, while Synopsys slipped more than 2.5% despite beating estimates after reaching an agreement with activist investor Elliott Investment Management to appoint Jesse Cohn to its board. Additionally, drone stocks rallied following reports that the Trump administration is in talks to provide funding, with Unusual Machines up 28% and Red Cat Holdings surging 14%.
📈 Dollar Tree and Snowflake surged after beating earnings and raising guidance.
🚀 Best Buy, Hormel, and Agilent stocks jumped on strong quarterly results.
☁️ Salesforce dipped slightly despite revenue beats and raised full-year outlook.
🤖 Drone stocks rallied 10-28% following reports of potential government funding.
💻 Tech giants like Dell rose after securing major defense contracts.
📈 Dollar Tree surged over 11% after reporting Q1 adjusted earnings of $1.74 per share, beating the $1.53 analyst consensus.
💰 Revenue and guidance for both the current quarter and full year also exceeded expectations for the discount retailer.
🚀 The company announced a new partnership with DoorDash to enable on-demand delivery from its stores to consumers.
📉 Salesforce shares dipped 1% despite beating Q1 earnings and revenue, as it guided for $11.27B-$11.35B in current-quarter revenue.
🔼 Salesforce raised its full-year earnings guidance range after posting a beat on both the top and bottom lines.
🧬 Agilent Technologies shares jumped 9% following a Q2 beat and an upgrade to full-year adjusted earnings guidance to $6-$6.10 per share.
🛒 Best Buy stock rose nearly 8% after beating Q1 earnings and revenue, with comparable sales up 2% year-over-year.
💻 Marvell Technology slipped almost 3% despite posting a rosy outlook and beating Q1 estimates for adjusted earnings of 93 cents per share.
🥩 Hormel Foods shares popped 10% after reporting fiscal Q2 adjusted earnings of 40 cents, surpassing the 35-cent analyst consensus.
☁️ Snowflake soared nearly 37% after beating Q1 estimates with $1.39 billion in revenue and 39 cents per share in adjusted earnings.
🤝 Snowflake also announced a plan to spend $6 billion on Amazon Web Services over the next five years.
📊 DataDog rose 6% and ServiceNow gained more than 5.5% in premarket trading, supported by Snowflake's strong performance.
💾 Nutanix added 2% after beating Q3 adjusted earnings and revenue, with a non-GAAP operating margin of 22.3%.
📉 Braze shares tumbled 10% after reporting Q1 adjusted earnings in line with expectations but missing on gross margin estimates.
🏪 Burlington Stores fell 3.5% despite beating Q1 earnings and revenue, though it plans to open 115 net new stores this year.
📉 Kohl's shares rose almost 11% after reporting a narrower-than-expected Q1 loss of 13 cents per share versus an expected 19-cent loss.
⚡ American Superconductor slid nearly 7% even though it expects current-quarter adjusted earnings to exceed 17 cents per share.
🏦 NCino shares climbed 12.5% after raising full-year revenue guidance to $642M-$646M, up from prior estimates of $639M-$643M.
🚁 Drone stocks rallied broadly after reports that the Trump administration is in talks to provide funding to some companies.
📈 Unusual Machines surged 28%, Red Cat Holdings jumped 14%, and Kratos Defense & Security Solutions popped 10% on drone sector news.
💻 Dell Technologies stock rose 4% after winning a $9.7 billion contract with the Pentagon to provide software to the Department of Defense.
☁️ Nebius Group, a Dutch cloud provider, rose 10% after a hedge fund operated by a former OpenAI employee re
Bullish Signals
- Dollar Tree surged 11% on earnings beat and raised guidance.
- Salesforce raised full-year guidance despite slight share dip.
- Agilent shares popped 9% after raising full-year earnings guidance.
- Best Buy rose 8% on earnings beat and comparable sales growth.
- Marvell posted rosy outlook with adjusted earnings beating estimates.
- Hormel Foods shares jumped 10% on earnings beat.
- Everpure beat earnings and revenue with higher operating income guidance.
- Snowflake soared 37% on earnings beat and AWS spending plan.
- ServiceNow and DataDog rose over 5% supported by Snowflake surge.
- Synopsys results surpassed estimates with adjusted earnings of $3.35.
- Nutanix beat earnings and revenue with 22.3% operating margins.
- Burlington Stores plans 115 new stores despite stock decline.
- Kohl's shares up 11% on narrower-than-expected loss.
Risk Factors
- Synopsys shares slipped 2.5% amid Elliott board appointment signaling governance instability.
- Braze stock tumbled 10% after missing gross margin estimates of 68.8%.
- Burlington Stores fell 3.5% as market prices concerns beyond current performance.
- American Superconductor slid 7% despite beating earnings, suggesting a consensus miss.
- Snowflake's $6 billion AWS spend raises capital expenditure and margin pressure fears.
Bullish Signals
- Dollar Tree surged more than 11% after reporting adjusted earnings of $1.74 per share, beating analyst estimates of $1.53 per share.
- Dollar Tree's revenue came in above expectations, and the company raised both current quarter and full-year guidance.
- Salesforce raised its full-year earnings guidance range despite a slight dip in shares, following a first-quarter earnings and revenue beat.
- Agilent Technologies shares popped 9% after raising full-year adjusted earnings guidance to between $6 and $6.10 per share, higher than previous estimates.
- Best Buy stock rose almost 8% after an earnings and revenue beat, with comparable sales up 2% year-over-year led by gaming and computing.
- Marvell Technology slipped slightly but posted a rosy outlook with adjusted earnings of 93 cents per share, beating the Street's expectation of 90 cents.
- Hormel Foods shares popped 10% after reporting fiscal second-quarter adjusted earnings of 40 cents, exceeding analyst expectations of 35 cents.
- Everpure reported a first-quarter adjusted earnings and revenue beat, with operating income guidance for the current quarter and full year exceeding estimates.
- Snowflake soared nearly 37% after surpassing estimates with adjusted earnings of 39 cents per share and revenue of $1.39 billion.
- Snowflake announced a plan to spend $6 billion on Amazon Web Services over five years, signaling strong cloud adoption.
- ServiceNow and DataDog rose more than 5% in premarket trading, supported by Snowflake's earnings surge.
- Synopsys second-quarter results surpassed Wall Street estimates with adjusted earnings of $3.35 per share on revenue of $2.28 billion.
- Nutanix reported a fiscal third-quarter adjusted earnings and revenue beat with non-GAAP operating margins at 22.3%, topping analyst calls.
- Burlington Stores plans to open 115 net new stores throughout the year, despite a slight stock decline.
- Kohl's shares were up almost 11% after reporting a narrower-than-expected loss of 13 cents per share versus an expected loss of 19 cents.
- NCino raised its full-year revenue guidance to a range of $642 million to $646 million, exceeding prior estimates.
- Drone stocks saw significant gains after reports of potential government funding talks, with Unusual Machines up 28% and Red Cat Holdings up 14%.
- Dell Technologies stock rose 4% after winning a $9.7 billion contract with the Pentagon to provide software to the Department of Defense.
Risk Factors
- Synopsys shares slipped more than 2.5% despite beating estimates, following an agreement with activist Elliott Investment Management that appoints Jesse Cohn to its board effective June 1, signaling potential governance instability.
- Braze shares tumbled 10% after reporting first-quarter adjusted earnings in line with expectations but missing gross margin estimates of 68.8%, coming in at only 67.4%.
- Burlington Stores fell 3.5% despite beating earnings and revenue estimates, indicating that the market may be pricing in concerns beyond current quarterly performance.
- American Superconductor stock slid almost 7% even after reporting adjusted earnings exceeding expectations of 17 cents per share versus analyst forecasts of 22 cents, suggesting a significant earnings miss relative to consensus.
- Snowflake's massive $6 billion planned spend on Amazon Web Services over five years raises concerns about high capital expenditure and potential margin pressure in the future.
Agilent Technologies (Ticker A) has been upgraded to a Zacks Rank #2, classified as a "Buy" by Zacks Investment Research. This upgrade is driven by a recent upward trend in earnings estimates for the scientific instrument maker, which serves as the sole determinant for Zacks ratings rather than subjective analyst recommendations. The system tracks the consensus EPS estimate from sell-side analysts and correlates rising estimates with improved underlying business fundamentals that historically lead to stock price increases. Specifically, for the fiscal year ending October 2026, analysts expect Agilent to earn $5.95 per share, unchanged from the previous year's reported figure, while the Zacks Consensus Estimate has risen by 0.3% over the past three months.
The article emphasizes that institutional investors rely on these earnings revisions to calculate fair value, often resulting in significant buying or selling pressure that moves stock prices accordingly. By placing a stock in the top 20% of its universe based on estimate revisions, the "Buy" rating indicates superior performance relative to market conditions. Zacks distinguishes itself from Wall Street analyst consensus by maintaining an equal proportion of buy and sell ratings across its entire coverage of over 4,000 stocks, ensuring that only the top performers receive favorable classifications regardless of market sentiment.
The text suggests that tracking such earnings estimate revisions is a proven strategy for individual investors aiming to capitalize on near-term stock movements. It notes that this method avoids the bias often found in analyst ratings systems which tend toward bullish recommendations. The report concludes by positioning Agilent as a solid candidate for producing market-beating returns due to its placement among stocks with the strongest earnings estimate revision features, directing readers to further resources for daily Zacks Rank recommendations and free stock analysis reports.
Agilent upgraded to Zacks Rank #2 ("Buy") due to rising earnings estimates.
This objective rating places Agilent among the top 20% of all stocks.
Analyst consensus for fiscal 2026 expects $5.95 earnings per share.
- 📈 Agilent Technologies (A) has been upgraded to a Zacks Rank #2, which is classified as a "Buy" rating.
- 📊 This upgrade is driven by an upward trend in earnings estimates rather than subjective analyst opinions.
- ⚖️ The Zacks rating system maintains a neutral balance of buy and sell ratings across its 4,000+ covered stocks.
- 🏆 Only the top 20% of stocks receive a "Buy" or "Strong Buy" ranking within this system.
- 📈 An upgrade to Rank #2 places Agilent in the top 20% of stocks for earnings estimate revisions.
- 💰 The sole determinant of this rating is the company's changing earnings picture tracked by analysts.
- 🤖 Institutional investors heavily influence stock price movements based on changes in earnings estimates.
- 📉 Empirical research shows a strong correlation between rising earnings estimates and near-term stock price increases.
- 🔭 For the fiscal year ending October 2026, Agilent is expected to earn $5.95 per share.
- 📈 Analyst consensus estimates for Agilent have increased by 0.3% over the past three months.
- ⚙️ The company's underlying business improvement is reflected in these rising earnings projections.
- 📊 Wall Street analyst ratings can be overly optimistic, whereas Zacks uses objective mathematical models.
- 🔍 Zacks Rank #1 stocks have historically generated an average annual return of +25% since 1988.
- 🚀 The positive shift in earnings outlook could translate into buying pressure and a rise in stock price.
- 📉 Rating systems based on subjective factors are difficult to measure in real time compared to earnings data.
Bullish Signals
- Agilent (A) upgraded to Zacks Rank #2 Buy.
- Earnings estimates rose 0.3% over the last three months.
- Ranks in top 20% for estimate revisions.
- Institutional interest often drives price appreciation.
Risk Factors
- Flat earnings expected for FY Oct 2026.
- Agile earnings forecast contradicts improving trend narrative.
Bullish Signals
- Agilent Technologies (A) has been upgraded to a Zacks Rank #2 (Buy), signaling a positive upward trend in earnings estimates which is a powerful force driving stock prices higher.
- Analysts have steadily raised their estimates for Agilent, with the Zacks Consensus Estimate increasing by 0.3% over the past three months.
- The upgrade positions Agilent in the top 20% of all covered stocks based on superior earnings estimate revisions, indicating strong potential for market-beating returns.
- Institutional investors typically increase their holdings and drive price appreciation when they perceive improvements in a company's underlying business and earnings outlook.
Risk Factors
- For the fiscal year ending October 2026, Agilent's earnings are expected to remain flat at $5.95 per share, unchanged from the prior year, which contradicts the bullish narrative of an 'improving business trend'.
Agilent Technologies Inc. reported its fiscal 2026 first-quarter results on February 25, 2026, missing Wall Street expectations by one cent with adjusted earnings per share of $1.37 versus consensus estimates of $1.36, while revenue came in slightly below forecasts at approximately $1.80 billion compared to the expected $1.81 billion. Despite this narrow earnings miss, management indicated that the top-line trajectory remains positive with 7.0% year-over-year revenue growth, signaling continued demand for the company's analytical instruments and consumables in life science, pharmaceutical, and biotechnology sectors. The company’s performance reflects a mix of upfront hardware sales and recurring revenue streams from consumables such as columns and reagents, which provide stability once laboratory installations are established.
Looking ahead, Agilent Technologies issued second-quarter 2026 guidance projecting adjusted EPS between $1.39 and $1.42 with revenue near $1.8 billion, figures that align closely with prevailing analyst forecasts. Consensus expectations for the coming year suggest earnings could grow from approximately $5.95 per share to $6.55 per share, representing over 10% growth driven by resilient demand in drug discovery, diagnostics, and genomics markets. The company also maintains a commitment to shareholder returns through a regular dividend program, with a recent quarterly payment of $0.25 per share yielding around 0.90% at recent price levels.
Business-wise, Agilent focuses on chromatography, mass spectrometry, spectroscopy, and diagnostics platforms that serve critical roles in research, quality control, and clinical workflows across healthcare systems. The firm also leverages service offerings including maintenance contracts and compliance support to capture higher-margin revenue while addressing customer needs regarding cost pressures and staffing challenges. While regulatory dynamics in the diagnostics arena present certain sensitivities, the broader trend toward precision medicine and increased testing volumes supports long-term structural growth for Agilent’s portfolio of laboratory equipment and solutions.
📉 Q1 2026 EPS missed by $0.01 while revenue grew 7% year-over-year to $1.8 billion.
💰 Q2 guidance shows strong alignment with forecasts as long-term earnings are expected to rise over 10%.
🧬 Business model blends hardware sales, consumables, and services driving stable cash flows across key industries.
📉 Agilent Technologies reported Q1 2026 adjusted earnings per share of $1.36, missing analyst consensus estimates by $0.01.
💰 Revenue for the first quarter was approximately $1.80 billion, slightly below the projected $1.81 billion but showing a 7% year-over-year increase.
📅 The results were released on February 25, 2026, marking the company's start to its fiscal 2026 with modest growth amidst macroeconomic uncertainties.
🔮 Management issued Q2 2026 guidance projecting EPS between $1.39 and $1.42 with revenue near $1.8 billion, aligning closely with analyst forecasts.
📈 Long-term consensus estimates suggest earnings could rise from roughly $5.95 to $6.55 per share over the next year, indicating growth of just over 10%.
💵 The stock traded around $112.80 on May 13, 2026, and recently paid a quarterly dividend of $0.25 per share with an ex-dividend date of March 31, 2026.
🧬 Agilent's portfolio focuses on analytical instruments like chromatography and mass spectrometry used in pharmaceutical, biotechnology, and chemical markets.
⚙️ The business model combines upfront hardware sales with recurring revenue from consumables such as columns and reagents needed for installed base maintenance.
🔬 Diagnostic and genomics segments supply assays and instruments for clinical testing in areas like oncology and genetic analysis, tapping into precision medicine trends.
🛠 Service offerings including maintenance contracts, qualification support, and training help capture higher-margin revenue while deepening customer relationships.
⚖️ The narrow earnings miss is attributed to margin pressures or product mix effects rather than a loss of underlying growth drivers in core end markets.
🧪 Laboratory equipment faces recurring demand as customers run tests and maintain instruments, supporting stable cash flows despite budget constraints for some academic clients.
🏥 Solutions used in quality-control and clinical workflows are integral to research processes across various industries including environmental and chemical sectors.
Bullish Signals
- Agilent Q1 FY26 revenue grew 7.0% YoY.
- Company raised Q2 FY26 EPS guidance to $1.39-$1.42.
- Earnings expected to rise from $5.95 to $6.55 next year.
- Recurring consumables sales ensure ongoing demand post-installation.
- Quarterly dividend is $0.25 with a 0.90% yield.
- Service contracts offer higher-margin revenue and deepened relationships.
Risk Factors
- Missed Q1 EPS target by $0.01, reporting $1.36 vs $1.37.
- Q1 revenue fell slightly short at $1.80B versus $1.81B expected.
- Margin pressures and mix effects limited earnings upside growth.
- Low 0.90% dividend yield may deter income-focused investors.
Bullish Signals
- Agilent Technologies reported a 7.0% year-over-year revenue growth in the first quarter of fiscal 2026, demonstrating solid demand across core end markets despite macroeconomic uncertainty.
- The company raised its second-quarter 2026 guidance, projecting EPS between $1.39 and $1.42, with projections broadly aligned to analyst consensus for continued expansion.
- Long-term consensus expectations indicate that earnings could rise from about $5.95 per share to $6.55 per share over the next year, representing growth of just over 10%.
- Agilent maintains a recurring revenue model through consumables like columns and reagents sold alongside hardware, ensuring ongoing demand once instruments are installed in laboratories.
- The company returns cash to shareholders via a regular quarterly dividend of $0.25 per share with an attractive dividend yield of about 0.90% at recent prices.
- Service offerings in maintenance contracts and compliance support provide the opportunity to capture higher-margin service revenue and deepen customer relationships over time.
Risk Factors
- Agilent Technologies missed Q1 2026 earnings-per-share expectations by $0.01, reporting $1.36 versus the consensus estimate of $1.37.
- Revenue for the first quarter came in slightly below Wall Street projections at approximately $1.80 billion compared to the expected $1.81 billion.
- The earnings miss suggests that margin pressures or unfavorable mix effects limited upside despite positive top-line growth.
- Dividend yield is relatively low at 0.90% for a stock trading around $112.80, which may limit total return potential for income-focused investors.
Agilent Technologies has entered into a strategic licensing agreement with Cirena to deploy Agilent's long RNA purification technology specifically for genome editing applications. The partnership targets the scalable production of high purity long RNA constructs intended for CRISPR and functional genomics workflows, effectively expanding Agilent's footprint in synthetic RNA tools beyond its traditional diagnostics and measurement business. Under this arrangement, Agilent provides the core purification process while Cirena manages the synthesis and scale-up operations, allowing Agilent to gain exposure to the growing demand for CRISPR and functional genomics without undertaking significant capital expenditure on manufacturing facilities.
This development aligns with Agilent's broader strategy to position its portfolio across both translational research and clinical decision tools, supported by recent regulatory wins such as PD L1 companion diagnostics approvals. The licensing structure ties economics to Cirena's volume and customer uptake rather than large upfront spending, offering potential recurring revenue streams as long RNA purification supports repeat demand in advanced lab workflows. Investors should monitor how well Cirena integrates this technology into market-traction products, including new CRISPR workflow kits or references in genome editing collaborations, to gauge the deal's commercial success.
The article notes that while adoption of higher priced long RNA workflows could be slowed by tariff-driven costs or funding pressures in research budgets, the agreement still represents a meaningful expansion into next generation lab technologies. Risk factors include execution challenges if Cirena fails to scale production or compete with established tool providers like Thermo Fisher Scientific, Danaher, and Illumina that already hold strong relationships with major laboratories. Success in this sector will depend on maintaining capital discipline while leveraging Agilent's core expertise in sample prep and workflow software to influence future collaborations and revenue mix within the biotech research pipeline.
🤝 Agilent licenses long RNA purification tech to Cirena for genome editing.
💰 Deal avoids heavy capital investment by letting Cirena handle scale-up.
📈 Partnership expands Agilent's footprint in high-growth synthetic RNA workflows.
⚠️ Risks include execution challenges and potential adoption volatility from costs.
🔍 Investors should monitor uptake rates and new workflow kit integrations.
Agilent Technologies (NYSE:A) has licensed its long RNA purification technology to Cirena specifically for genome editing applications.
The strategic agreement focuses on enabling scalable production of high-purity long RNA constructs essential for CRISPR and functional genomics workflows.
This licensing move expands Agilent's footprint in synthetic RNA tools beyond its existing core offerings in diagnostics and measurement solutions.
Agilent avoids the capital intensity of building a full RNA production business while supplying a key process that addresses a bottleneck in RNA purity.
Cirena is responsible for synthesis and scale-up, allowing Agilent to maintain capital discipline and limit risk exposure to upfront spending.
The deal aligns with recurring revenue themes as long RNA purification can support repeat demand in next-generation research pipelines.
Analysts view the partnership as an extension of Agilent's reach into high-growth research workflows without altering its core business role.
Potential investors should monitor adoption rates of this technology within therapeutic and research pipelines for future revenue implications.
The agreement positions Agilent competitively alongside peers like Thermo Fisher Scientific, Danaher, and Illumina in the genome editing market.
Success risks include execution challenges if Cirena struggles to scale or win customers against established tool providers.
Demand volatility could occur if tariff-driven costs or tightened research funding budgets slow adoption of higher-priced long RNA workflows.
Future value may depend on tracking integration signs such as new CRISPR workflow kits, customer case studies, and management commentary.
The licensing economics suggest revenue ties to Cirena's volume and uptake rather than large upfront investments from Agilent.
This development follows regulatory wins in companion diagnostics, indicating a broader portfolio strategy across translational research and clinical tools.
Some current market narratives may understate the potential of RNA-focused follow-on agreements with other genome editing players.
Bullish Signals
- Agilent licensed long RNA tech to Cirena for genome editing revenue.
- Deal boosts CRISPR workflow growth without heavy upfront capital spending.
- Shares rose 2.7% this week and 10.0% last year on strength.
- Partnership aligns Agilent with peers Thermo Fisher and Danaher in RNA.
- Regulatory wins complement strategy across research and clinical diagnostic tools.
- Licensing ties revenue to volume, supporting capital discipline and lower risk.
- Extension into synthetic RNA diversifies product mix with low manufacturing exposure.
- Long RNA purification supports recurring demand in CRISPR lab workflows.
- Analysts see valuation rewards including earnings growth and trading below fair value.
Risk Factors
- Budget pressures may slow long RNA workflow adoption.
- Cirena faces scaling risks against competitors like Thermo Fisher and Illumina.
- RNA revenue streams are overlooked in current market narratives.
- Agilent lacks upside if Cirena partnership falters.
Bullish Signals
- Agilent has licensed its long RNA purification technology to Cirena for genome editing applications, creating new revenue streams without the large upfront capital spending associated with manufacturing.
- The licensing arrangement allows Agilent to maintain focus on its core strengths in measurement and workflow software while still capturing growth in high-demand CRISPR and functional genomics workflows.
- Agilent shares have already demonstrated recent strength, rising 2.7% over the past week and gaining 10.0% over the past year, signaling positive market sentiment ahead of the deal's full impact.
- The partnership positions Agilent alongside peers like Thermo Fisher Scientific and Danaher in the synthetic RNA production space, potentially leading to future collaborations with other RNA or gene editing players.
- Regulatory wins such as PD-L1 companion diagnostics approvals complement this strategic move, demonstrating management's ability to successfully position its portfolio across both translational research and clinical decision tools.
- The licensing structure ties economics to Cirena's volume rather than Agilent's capital expenditure, which supports capital discipline and reduces operational risk.
- Agilent is extending its presence in synthetic RNA tools beyond its existing diagnostics offerings, diversifying its product mix while maintaining low exposure to manufacturing build-outs.
- Next-generation lab technologies featuring recurring revenue potential are highlighted as a key narrative focus, with long RNA purification supporting repeat demand in CRISPR workflows.
- Analysts note that Agilent's current valuation may align with four identified rewards including forecast earnings growth and trading below some fair value estimates if the RNA opportunity develops well over time.
Risk Factors
- Adoption of the long RNA workflows could be slower than expected if tariff-driven costs or funding pressures cause research budgets to tighten.
- Execution risk exists if Cirena struggles to scale production or win customers in a competitive field where established providers like Thermo Fisher Scientific, Danaher, and Illumina already have deep relationships with major labs.
- The licensing economics and potential follow-on agreements may not be fully captured in the current market narrative, which is overly centered on instruments, diagnostics, and services rather than emerging RNA revenue streams.
- Agilent's expansion into synthetic RNA tools depends entirely on Cirena's success; if that partnership falters, Agilent faces limited upside from this specific growth initiative without bearing significant upfront manufacturing costs.
Agilent Technologies Inc. has appointed Michael Buckner as its new Chief Legal Officer, effective May 4, 2026. He succeeds Bret DiMarco, who resigned from his roles as senior vice president, chief legal officer, and secretary on the same date pursuant to a previously disclosed transition agreement. DiMarco will continue with the company as a special advisor until December 1, 2026, to facilitate a smooth handover of responsibilities. Buckner joins Agilent from Danaher Corp., where he served as vice president, deputy general counsel, and chief M&A counsel, bringing nearly three decades of experience in complex transactions, governance, and regulatory matters. His background includes leading global legal teams and driving major deals such as high-profile acquisitions and spin-offs at Danaher, with earlier roles at General Electric. This appointment is expected to strengthen Agilent's legal strategy as it advances its growth plans and manages regulatory and transactional risk across its global operations.
Agilent Technologies Inc., a global leader in analytical and clinical laboratory technologies, reported fiscal 2025 revenue of $6.95 billion and employs approximately 18,000 people worldwide. The company provides instruments, software, services, and scientific expertise to customers engaged in complex research and diagnostic settings. Its market presence spans analytical labs and clinical environments, where its platforms enable testing, measurement, and analysis across pharmaceuticals, life sciences, diagnostics, and related industries. Analysts note solid underlying fundamentals and a constructive earnings-call outlook, including maintained growth guidance, raised EPS estimates, and plans for margin expansion and tariff mitigation, though concerns remain regarding a weak technical setup and relatively high P/E ratio.
⚖️ Michael Buckner joins as new CLO effective May 4, 2026.
👋 Bret DiMarco steps down but stays as special advisor until Dec 1, 2026.
📈 Analysts rate Agilent stock as a Buy with a $140 price target.
💰 Fiscal 2025 revenue reached $6.95 billion globally.
👥 The company employs approximately 18,000 people worldwide.
🗂️ Agilent Technologies Inc. has appointed Michael Buckner as its new Chief Legal Officer, effective May 4, 2026.
👋 Bret DiMarco is stepping down from his roles as senior vice president, chief legal officer, and secretary on the same date.
🤝 DiMarco will transition into a special advisor role until December 1, 2026, to assist with the handover of responsibilities.
💼 Buckner brings nearly 30 years of experience from Danaher Corp., where he served as vice president and deputy general counsel.
⚖️ His background includes leading global legal teams for complex transactions, governance, and regulatory matters at major firms like General Electric.
📈 TipRanks analysts rate Agilent (A) stock as a Buy with a $140.00 price target.
🧠 Spark's AI Analyst gives Agilent a Neutral rating based on solid fundamentals but notes a weak technical setup.
💰 Positive factors include maintained growth guidance, raised EPS, and margin-expansion plans offset by a high P/E ratio.
🔬 Agilent reported fiscal 2025 revenue of $6.95 billion across analytical and clinical laboratory technologies.
👥 The company employs approximately 18,000 people worldwide focusing on instruments, software, and services for scientific research.
Bullish Signals
- Agilent appointed Michael Buckner as CLO on May 4, 2026 with nearly 30 years experience.
- Buckner joins from Danaher Corp. to strengthen legal strategy for growth plans.
- Analysts maintain a Buy rating on Agilent with a $140.00 price target.
- Agilent reported fiscal 2025 revenue of $6.95 billion and employs about 18,000 people.
- Company maintained growth guidance and raised EPS for the upcoming period.
- Management plans margin expansion and tariff mitigation to support future profitability.
Risk Factors
- CEO DiMarco resigned May 4, 2026 amid leadership transition.
- Stock trades below moving averages with negative momentum.
- High P/E ratio and low dividend yield pose risks.
- Conflicting analyst signals between Buy rating and Neutral AI score create uncertainty.
Bullish Signals
- Agilent appointed Michael Buckner as its new Chief Legal Officer on May 4, 2026, bringing nearly 30 years of experience in complex transactions and governance.
- Buckner joins from Danaher Corp., where he drove major deals including high-profile acquisitions and spin-offs, expected to strengthen Agilent's legal strategy as it advances its growth plans.
- Analysts maintain a Buy rating on Agilent with a $140.00 price target.
- The company reported fiscal 2025 revenue of $6.95 billion and employs about 18,000 people worldwide.
- Agilent has maintained its growth guidance and raised EPS for the upcoming period.
- Management outlined plans for margin expansion and tariff mitigation to support future profitability.
Risk Factors
- Bret DiMarco resigned from his roles as senior vice president, chief legal officer, and secretary on May 4, 2026, indicating a significant leadership transition amidst ongoing operations.
- The stock exhibits a weak technical setup characterized by trading below key moving averages with negative momentum, signaling potential downside pressure.
- Despite maintaining growth guidance, the valuation presents risks due to a relatively high P/E ratio coupled with a low dividend yield.
- Recent analyst consensus includes conflicting signals between a 'Buy' rating and a 'Neutral' AI score, creating uncertainty in investment sentiment.
Promex Industries and its QP Technologies division have announced the appointment of David Fromm as president and chief operating officer, effective immediately. The leadership change comes from Dick Otte, CEO of Promex Industries and QP Technologies, who stated that After more than 30 years leading the organization, he is pleased to pass the role to Fromm. Fromm brings deep expertise in advanced instrumentation, process development, and technology leadership to the expanded role. Since joining Promex in 2023, he has been instrumental in developing specialized manufacturing processes for complex microelectronics assemblies, earning the trust of both customers and leadership. In his new capacity, Fromm will oversee strategic direction, operational execution, and continued growth across Promex and QP Technologies.
Prior to joining Promex Industries in 2023, Fromm served as director of instrument research at Cepheid, where he led research and development efforts for next-generation hardware and technology platforms. His career also includes holding research positions at Agilent Technologies, which helped him build a strong foundation in precision instrumentation and scientific innovation. Educationally, Fromm holds a Ph.D. in physical chemistry from Stanford University and a B.A. in biochemistry from the University of Colorado Boulder. He is also an accomplished innovator who holds multiple patents in molecular diagnostics systems and high-speed atomic force microscopy.
Fromm expressed honor and excitement about taking on the role, emphasizing that Over the decades, Promex and QP Technologies have built something truly special: a reputation for solving the hardest problems in microelectronics assembly and delivering for customers when it matters most. He stated his focus will be on building on that foundation, investing in their people, expanding their capabilities, and continuing to be the partner their customers turn to for their most demanding applications. He believes the market for advanced microelectronics assembly is growing and noted that they are exceptionally well positioned to serve it. Founded in 1975, Promex Industries specializes in advanced microelectronics packaging and assembly for mission-critical applications across defense, medical, aerospace, and commercial markets, while QP Technologies has been a division since 2015 serving customers with exacting standards for complex device fabrication.
📢 David Fromm appointed president and COO of Promex Industries and QP Technologies.
💼 Former Cepheid leader brings R&D expertise, PhD, and multiple patents to role.
🚀 New CEO Dick Otte hands over after 30 years to drive future growth.
📢 Promex Industries and its QP Technologies division appointed David Fromm as president and COO effective immediately.
💼 David Fromm brings extensive expertise in advanced instrumentation, process development, and technology leadership to the role.
🔬 Prior to joining Promex in 2023, Fromm served as director of instrument research at Cepheid, leading R&D for next-generation hardware platforms.
🎓 Fromm holds a Ph.D. in physical chemistry from Stanford University and a B.A. in biochemistry from the University of Colorado Boulder.
🛡 He holds multiple patents in molecular diagnostics systems and high-speed atomic force microscopy, highlighting his innovative capabilities.
✅ Promex CEO Dick Otte stated that he is pleased to pass the presidency to Fromm after more than 30 years leading the organization.
📈 Management believes Fromm possesses the skills and vision to take both companies to the next stage of growth amid expanding markets.
🔄 The appointment underscores a commitment to continuity and operational excellence for trusted advanced microelectronics assembly partners.
🚀 Fromm plans to focus on investing in people, expanding capabilities, and serving demanding applications in the growing market.
📅 Promex Industries was founded in 1975 and specializes in advanced microelectronics packaging and assembly for defense, medical, aerospace, and commercial sectors.
🔍 QP Technologies has been a division of Promex since 2015 and is a leading provider of high-reliability microelectronics solutions.
Bullish Signals
- David Fromm brings deep expertise in advanced instrumentation, process development, and technology leadership to his expanded role as President and Chief Operating Officer.
- Since joining Promex, Fromm has been instrumental in developing specialized manufacturing processes for complex microelectronics assemblies, earning the trust of both customers and leadership.
- CEO Dick Otte highlighted that Fromm has demonstrated a keen ability to develop advanced manufacturing processes while managing the complexity of a growing business.
- Fromm will oversee continued growth across Promex Industries and QP Technologies in strategic markets including defense, medical, aerospace, and commercial.
- The market for advanced microelectronics assembly is described as growing, positioning the company to serve it exceptionally well under Fromm's leadership.
Risk Factors
- The departure of Dick Otte, who led the organization for more than 30 years, to the CEO role introduces uncertainty regarding long-term strategic stability under new leadership.
- David Fromm is taking over the president and COO roles 'effective immediately' without a stated transition period, potentially causing operational disruption or integration challenges during this sudden change.
Agilent Technologies Inc., traded on the New York Stock Exchange under the ticker A, has announced it will release financial results for its second quarter of fiscal year 2026. The earnings report is scheduled to be made available after the stock market closes on Wednesday, May 27. In conjunction with the release, the company plans to host a listen-only conference call webcast at 1:30 p.m. PDT on the same day to discuss the quarter's performance. Interested parties can access the webcast by clicking a link in the Events section of Agilent's Investor Relations website, and a recording will remain available for 90 days following the call.
Agilent Technologies positions itself as a global leader in analytical and clinical laboratory technologies, offering instruments, software, services, and expertise to help customers solve challenging questions. The company has previously reported revenue of $6.95 billion for fiscal year 2025 and maintains an employee base of approximately 18,000 people worldwide. Further information regarding the company and its latest developments can be found on the Agilent Newsroom, and subscribers can follow updates via LinkedIn and Facebook.
The press release also includes mentions of other recent science and technology business news, such as BC.GAME Esports signing Mongolian player Azbayar "Senzu" Munkhbold and VertiGIS acquiring 1Spatial for a deal valued at £87 million. Additionally, Agilent notes that its full range of solutions is designed to deliver trusted answers and bring great science to life. The news was published on April 28, 2026, and distributed through various channels covering the sectors of Science, Technology, and Business.
📅 Agilent releases FY26 Q2 results May 27 after market close.
📞 Listen-only earnings call at 1:30 p.m. PDT May 27.
💼 Global leader in analytical lab technologies with $6.95B FY25 revenue.
📅 Agilent Technologies will release fiscal year 2026 second-quarter financial results after market close on Wednesday, May 27.
📞 The company will host a listen-only conference call to discuss the results at 1:30 p.m. PDT on May 27.
🌐 A recording of the earnings call will be available on Agilent's Investor Relations website for 90 days.
🔗 Investors can access the live webcast via the Events section of the Agilent Investor Relations website.
💼 Agilent is a global leader in analytical and clinical laboratory technologies providing instruments, software, and services.
📊 The company generated total revenue of $6.95 billion during fiscal year 2025.
👥 Agilent currently employs approximately 18,000 people worldwide across its operations.
Bullish Signals
- Agilent is a global leader in analytical laboratory technologies.
- FY2025 revenue reached $6.95B with 18,000 employees worldwide.
- Solutions span instruments, software, and services to answer customer challenges.
Risk Factors
- Agilent hasn't released Q2 FY2026 results, creating investor uncertainty.
- Earnings could disappoint without prior interim updates or guidance.
- No positive news as Agilent relies on future financial disclosures.
Bullish Signals
- Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation to help customers bring great science to life.
- The company generated strong revenue of $6.95 billion in fiscal year 2025, demonstrating consistent market performance with approximately 18,000 employees worldwide supporting its operations.
- Agilent's full range of solutions, including instruments, software, services, and expertise, provides trusted answers to customers' most challenging questions, underscoring the company's technological depth.
Risk Factors
- Agilent has not yet released its Second-Quarter Fiscal Year 2026 Financial Results, leaving investors uncertain about the company's performance until after May 27.
- The upcoming earnings announcement could reveal disappointing metrics given the lack of interim updates or positive guidance prior to the release date.
- With no positive operational news highlighted in this press release, Agilent relies solely on future financial disclosure to support its market valuation.
Agilent Technologies Inc. (NYSE: A) has announced that it will release its second-quarter fiscal year 2026 financial results on Wednesday, May 27, following the close of stock market trading in Santa Clara, California. The company plans to hold a conference call and audio webcast at 1:30 p.m. PDT on May 27 to discuss these results and provide updates. Investors can access the listen-only webcast through the Events section of Agilent's Investor Relations website, with recordings available for a period of 90 days after the presentation. Agilent, which employs approximately 18,000 people worldwide, generated revenue of $6.95 billion in fiscal year 2025 and operates as a global leader in analytical and clinical laboratory technologies.
Separately, argenx (Euronext & Nasdaq: ARGX), a global immunology company based in Amsterdam, announced it will host a conference call and audio webcast on Thursday, May 7, 2026, at 2:30 PM CET to discuss its first quarter 2026 financial results and provide a business update. The live call is accessible via the Investors section of argenx.com, with replays available for approximately one year. The company utilizes an access code of 3810049 for participants to join the call, with instructions to dial in 15 minutes prior. Argenx focuses on developing novel antibody-based medicines, including its first approved neonatal Fc receptor (FcRn) blocker for severe autoimmune diseases, supported by its Immunology Innovation Program (IIP).
Additionally, AMG Critical Materials N.V. (EURONEXT AMSTERDAM: AMG), based in Amsterdam, will release its first quarter 2026 financial results on Wednesday, May 6, 2026, at approximately 18:00 CEST. A conference call to discuss these results is scheduled for Thursday, May 7, 2026, at 09:00 CEST (3:00 a.m. EDT). The call-in information includes toll-free and international numbers for various regions, such as the United States, United Kingdom, Netherlands, and Japan, with a conference ID of AMGQ12026. AMG is dedicated to providing critical materials for energy storage technologies including lithium, vanadium, and tantalum, aiming to reduce CO2 footprints across multiple industries while maintaining operations in over 15 countries with approximately 3,600 employees.
📅 Agilent reports F26 Q2 results May 27 with webcast available on its investor site.
💼 Revenue reached $6.95B in FY2025; Argenx hosts Q1 call May 7 at 2:30 PM CET.
⚙ AMG releases Q1 F26 data Wednesday and calls Thursday, focusing on critical materials.
📅 Agilent will release second-quarter fiscal year 2026 financial results on Wednesday, May 27 after the stock market closes.
📞 A conference call to discuss results is scheduled for 1:30 p.m. PDT with a webcast available on Agilent's Investor Relations website.
🎧 A recording of the call will remain accessible for 90 days following the presentation.
💼 Agilent generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide.
📱 Investors can find details on Agilent's website and subscribe to the Agilent Newsroom for updates.
🤝 Argenx announced it will host a conference call on Thursday, May 7 at 2:30 PM CET to discuss first quarter 2026 financial results.
🔬 Argenx is a global immunology company developing novel antibody-based medicines for severe autoimmune diseases.
📞 The live webcast can be accessed via the Investors section of argenx.com with replay availability for approximately one year.
💊 Argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker for serious autoimmune diseases.
🌐 Argenx partners with leading academic researchers through its Immunology Innovation Program (IIP).
⚙️ AMG Critical Materials will release first quarter 2026 financial results on Wednesday, May 6 at approximately 18:00 CEST.
📞 A conference call for AMG is scheduled for Thursday, May 7 at 09:00 CEST with dial-in numbers and a conference ID provided.
🌍 AMG produces critical materials including lithium, vanadium, and tantalum to advance a less carbon-intensive world.
⚡ AMG segments focus on energy storage materials, recycling vanadium, and reducing CO2 in aerospace engines.
🏭 AMG operates globally with production facilities across Europe, the Americas, Asia, and other regions employing approximately 3,600 people.
⚠️ AMG press release includes forward-looking statements regarding future plans, projections, and operations that are not historical facts.
Bullish Signals
- Agilent is a global leader in analytical and clinical lab technologies.
- Agilent generated $6.95 billion revenue in fiscal year 2025.
- Agilent employs approximately 18,000 people worldwide.
- AMG operates globally with production facilities across 10 countries.
- AMG is a world leader in recycling vanadium from oil refining residues.
- AMG leads advanced metallurgy for the aerospace engine sector globally.
- Agilent's LIVA batteries show expansion into new energy storage markets.
- AMG entered the nuclear fuel market with NewMOX SAS.
Risk Factors
- Agilent adds Q2 FY26 results date to crowded spring calendar.
- Release lacks guidance, raising revenue and profit uncertainty.
- Argenx call time at 2:30 PM CET may misalign with investors.
Bullish Signals
- Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies with a full range of solutions including instruments, software, services, and expertise.
- The company generated significant revenue of $6.95 billion in fiscal year 2025, demonstrating strong financial performance.
- Agilent employs approximately 18,000 people worldwide, highlighting its substantial scale and operational reach.
- AMG Critical Materials N.V. operates globally with production facilities across 10 countries including Germany, the United Kingdom, France, the United States, China, Mexico, Brazil, India, and Sri Lanka.
- AMG is a world market leader in recycling vanadium from oil refining residues through its Vanadium segment.
- AMG is an established world market leader in advanced metallurgy providing equipment engineering to the aerospace engine sector globally.
- The company's fast-growing LIVA batteries indicate expanding innovation and growth potential in new energy storage markets.
- AMG has formed NewMOX SAS specifically to span the nuclear fuel market, demonstrating strategic expansion into emerging high-growth sectors.
Risk Factors
- Agilent is set to announce second-quarter fiscal year 2026 financial results on May 27, adding another earnings date to a crowded spring quarter calendar that includes argenx (May 7) and AMG Critical Materials (May 6).
- The press release focuses exclusively on the announcement of upcoming financial results with no accompanying guidance or discussion of business performance, creating heightened uncertainty around future revenue and profit expectations.
- Argenx's conference call on May 7 is scheduled at 2:30 PM CET (8:30 AM ET), which may not align well with all investor time zones given its European headquarters.
The Carillon Scout Mid Cap Fund Q1 2026 portfolio review highlights the continued dominance of hyperscalers while noting significant growth in smaller AI-focused cloud data center operators during the first quarter of 2026. The commentary identifies several key holdings including Teradyne (TER), which is benefiting from increased semiconductor testing complexity for AI accelerator, networking, and memory chips. Ciena (CIEN) is highlighted for its design and manufacturing of advanced optical networking hardware, including transport systems and pluggable transceivers, though the specific stock performance description was cut off in the provided text.
Investor sentiment appears mixed regarding other holdings, with Agilent lagging in the first quarter despite posting solid headline results. This underperformance is attributed to investor focus on softer underlying trends rather than overall financial performance. The review also lists a comprehensive set of tickers associated with the portfolio including MPC, ATI, CASY, MDB, TTAN, CPNG, A, HOOD, and others, indicating a diverse range of mid-cap positions beyond the specifically analyzed semiconductor and networking sectors.
The article notes that this content was excerpted from a broader commentary by Raymond James Investment Management, a global asset-management firm that emphasizes combining individual investment team agility with institutional-class portfolio managers. The review is part of the firm's long-term strategy to help investors achieve financial goals, though it includes a disclaimer stating the Seeking Alpha account hosting this review is not managed or monitored by Raymond James Investment Management and readers should use official channels for inquiries. The publication date is April 28, 2026, reflecting the fund's performance through the end of the first quarter in that fiscal year.
🚀 Hyperscalers led market trends while small AI cloud operators grew rapidly.
🧪 Teradyne benefits from increased semiconductor test complexity for AI chips.
📉 Agilent underperformed Q1 despite solid headline results due to softer demand.
💻 Ciena offers advanced optical networking hardware and transceivers.
📅 Review reflects Carillon Scout Mid Cap Fund Q1 2026 commentary released April 28.
🚀 Hyperscalers drove market trends while emerging groups like small AI-focused cloud data center operators saw rapid growth.
🧪 Teradyne stands to gain from rising semiconductor test complexity related to AI accelerators, networking, and memory chips.
📉 Agilent underperformed in Q1 despite solid headline results due to softer underlying investment focus.
💻 Ciena specializes in advanced optical networking hardware including transport systems and pluggable transceivers.
📅 This review reflects the Carillon Scout Mid Cap Fund's Q1 2026 portfolio commentary released on April 28, 2026.
Bullish Signals
- Hyperscalers drove strong infrastructure demand.
- Smaller AI cloud operators showed rapid growth.
- Teradyne benefits from rising semiconductor test complexity.
- Ciena manufactures advanced optical networking hardware.
Risk Factors
- Agilent lagged in Q1 despite solid results.
- Hyperscalers lead trend; smaller cloud operators growing fast.
Bullish Signals
- Hyperscalers led the trend with strong performance, indicating robust demand in the infrastructure sector.
- Smaller AI-focused cloud data center operators grew rapidly, highlighting upside potential in emerging customer groups.
- Teradyne benefits from increasing semiconductor test complexity for AI accelerator, networking, and memory chips, positioning it well for continued growth.
- Ciena designs and manufactures advanced optical networking hardware including transport systems and pluggable transceivers, serving key infrastructure needs.
Risk Factors
- Agilent lagged in the first quarter despite posting solid headline results, as investors focused on a few softer underlying trends.
- The Carillon Scout Mid Cap Fund commentary highlights that Hyperscalers led the trend while emerging customer groups such as smaller AI-focused cloud data center operators grew rapidly, potentially intensifying competitive pressure.
Agilent Technologies, Inc. (NYSE: A) has experienced notable share price volatility recently, with prices fluctuating between US$110 and a high of US$140 before settling around US$116 at the time of this analysis. The article questions whether the current trading price of US$116 reflects the company's intrinsic value or if it represents an undervalued opportunity. According to Simply Wall St’s valuation model, the stock appears fairly valued at present, trading approximately 7.7% below its calculated intrinsic value of US$125.15, suggesting there is limited immediate upside potential without further price dips.
Despite the current fair valuation, Agilent Technologies presents an attractive long-term outlook with projected profit growth of 55% expected over the next few years, which could drive higher cash flows and increase share valuation subsequently. The stock exhibits a high beta, indicating greater volatility relative to the broader market; this characteristic suggests that while the price may not significantly rise from current levels, there is potential for further downside movement that could create buying opportunities for investors seeking to buy low.
The analysis concludes that now might not be the optimal entry point for new investors as the market appears to have already priced in the company's positive prospects, trading near its fair value. Instead, the article advises prospective investors to examine other critical factors such as the strength of Agilent’s balance sheet and financial stability before committing capital. Investors are encouraged to monitor analyst forecasts and wait for a potential price drop below current fair value levels to improve their entry point timing, while noting that the stock is worth keeping on a watch list given its growth trajectory. The report explicitly states that this content is based on historical data and forecasts from Simply Wall St, and does not constitute financial advice or a direct recommendation to buy or sell the stock.
📉 Agilent shares at US$116, trading 7.7% below intrinsic value of US$125.15.
📈 Analysts predict significant profit growth of 55% over the coming years.
⚠ High volatility may signal better entry points despite strong financial fundamentals.
📉 Agilent Technologies (NYSE:A) shares recently traded between US$110 and US$140, currently sitting at US$116.
⚖️ Valuation models suggest the stock is fairly priced, trading approximately 7.7% below its calculated intrinsic value of US$125.15.
📈 Analysts forecast a significant profit growth of 55% over the next few years, pointing to a robust future outlook.
⚠️ High share volatility and beta levels indicate potential for further price dips could offer better entry points for investors.
🔍 Financial strength remains a key factor to examine alongside fair valuations when determining investment timing.
🚫 Investors seeking low-valuation opportunities now may find it challenging as the market has already priced in positive expectations.
🧾 This analysis from Simply Wall St relies on historical data and unbiased forecasts but does not constitute financial advice.
📊 The platform highlights Agilent Technologies alongside 21 other stocks forecasted to pay dividend yields over 6%.
Bullish Signals
- Shares hit US$140 high with upside potential.
- Trading at US$116, 7.7% below intrinsic value.
- Analysts forecast 55% profit growth over next years.
- Higher cash flows could lift long-term valuation.
- High beta suggests volatility for future buy opportunities.
Risk Factors
- Stock trading at $116, just 7.7% below $125 intrinsic value.
Bullish Signals
- Agilent Technologies' shares reached a high of US$140, indicating strong previous market attention and potential upside from the current price.
- The stock is trading at US$116, which is approximately 7.7% below its intrinsic value according to valuation models, presenting a margin of safety for investors.
- Analysts forecast significant profit growth of 55% over the next couple of years, suggesting a robust future outlook for the company.
- Expected higher cash flows from this growth trajectory could feed into an even higher share valuation in the long term.
- The company's high beta indicates increased volatility, which may offer opportunities to buy at lower prices in the future as the stock dips.
Risk Factors
- The stock is trading around US$116, which is only 7.7% below its intrinsic value of US$125.15, suggesting limited upside potential.
- Analyst forecasts suggest the market has already priced in Agilent Technologies' positive outlook, leaving little room for unexpected share price appreciation.
- The company's high beta indicates significant share price volatility, meaning prices could sink lower or rise unpredictably rather than following a steady trend.
- The article does not account for the latest price-sensitive company announcements or qualitative material, which could introduce unseen risks to investment decisions.
Agilent Technologies, Inc. (A), headquartered in Santa Clara, California, is a global leader valued at $34 billion that provides application-focused solutions for life sciences, diagnostics, and applied chemical markets. The company specializes in electronic and bio-analytical measurement, semiconductor, and board testing. Investors are anticipating the announcement of its fiscal second-quarter earnings for 2026, with analysts expecting a diluted profit of $1.41 per share, representing a 7.6% increase from the $1.31 per share reported in the year-ago quarter. Historically, the company has beat or matched consensus estimates in three of its last four quarters, though it missed forecasts on one occasion.
Looking at broader projections, analysts forecast full-year earnings per share (EPS) of $5.95, a 6.4% rise from fiscal 2025's $5.59. Growth is expected to accelerate in fiscal 2027, with an anticipated 10.1% year-over-year increase to reach $6.55 per share. Despite these growth projections, the stock has underperformed the S&P 500 Index’s 32.2% gains over the past 52 weeks, though it managed a 9% gain during that same period. Conversely, Agilent outperformed the State Street Health Care Select Sector SPDR ETF (XLV), which saw 7.7% gains in the same timeframe.
Recent performance highlights include the company's Q1 report on February 25, where shares closed down more than 3% following the results. During that quarter, adjusted EPS of $1.36 fell slightly below Wall Street expectations of $1.37, while revenue of $1.8 billion met forecasts. For the full year, management expects adjusted EPS between $5.90 and $6.04, with revenue anticipated to fall between $7.3 billion and $7.5 billion. The overall analyst consensus for Agilent stock remains bullish, supported by a "Strong Buy" rating from 11 out of 16 covering analysts, compared to one "Moderate Buy" and four "Hold" ratings. The average analyst price target is set at $162.64, suggesting potential upside of approximately 42.1% from current levels.
🧬 Agilent is a $34B global leader in laboratory technologies and diagnostics.
💰 Analysts project Q2 EPS of $1.41, beating last year's growth by 7.6%.
📈 Full-year EPS targets are $5.95 now, with long-term estimates reaching $6.55.
🏆 Experts rate Agilent "Strong Buy" with an average price target of $162.64.
💡 Recent missed Q1 earnings caused a dip, yet 11 analysts recommend buying.
- 🧬 Agilent Technologies is a $34 billion market cap global leader providing analytical and clinical laboratory technologies, diagnostics, and applied chemical solutions.
- 📅 The company is expected to announce its fiscal second-quarter earnings for 2026 in the near future ahead of analyst reports.
- 💰 Analysts project Agilent will report a diluted profit of $1.41 per share for the upcoming quarter, representing a 7.6% increase from the previous year's $1.31 per share.
- 📊 For fiscal full-year expectations, analysts anticipate an EPS of $5.95, which would be a 6.4% rise compared to $5.59 in fiscal 2025.
- 🚀 Long-term growth is projected with expected EPS reaching $6.55 by fiscal 2027, indicating a 10.1% year-over-year increase from current estimates.
- 📉 Despite recent gains, Agilent stock has underperformed the S&P 500's 32.2% gains over the past 52 weeks but still outperformed the Health Care Select Sector ETF.
- 📉 Following its Q1 report on Feb. 25 where adjusted EPS of $1.36 missed expectations, the stock closed down more than 3% in the subsequent trading session.
- 💵 In Q1, Agilent revenue stood at $1.8 billion, meeting Wall Street forecasts while management expects full-year revenue between $7.3 billion and $7.5 billion.
- 🎯 Analysts maintain a bullish consensus with an overall "Strong Buy" rating across 16 covering analysts.
- 💡 Out of the analyst coverage group, 11 advise "Strong Buy," one suggests "Moderate Buy," and four offer a "Hold" rating.
- 🏆 The average analyst price target for Agilent stock is set at $162.64, suggesting a potential upside of approximately 42.1% from current levels.
- ⚠️ Historical performance shows the company beat or matched consensus estimates in three of the last four quarters while missing the forecast on another occasion.
Bullish Signals
- Analysts project Agilent Technologies' fiscal second-quarter earnings per share (EPS) will reach $1.41, representing a 7.6% increase from the year-ago quarter's $1.31.
- The company demonstrated strong consistency in recent performance, beating or matching consensus estimates in three of its last four quarters.
- Full-year analysts expect Agilent to report an EPS of $5.95, which is a 6.4% increase from fiscal 2025's $5.59.
- Long-term growth is highlighted with expected fiscal 2027 EPS rising 10.1% year over year to $6.55.
- Despite underperforming the broader S&P 500, Agilent outperformed the State Street Health Care Select Sector SPDR ETF (XLV) with a 9% gain compared to 7.7% for the sector ETF.
- The stock carries a 'Strong Buy' rating from 16 analysts, with 11 explicitly advising this rating and an average price target suggesting 42.1% upside potential.
- Following Q1, revenue of $1.8 billion met Wall Street forecasts exactly, indicating operational resilience even after a slight miss in EPS.
Risk Factors
- The stock has underperformed the S&P 500 Index's 32.2% gains over the past 52 weeks, with shares rising only 9% during this period.
- Agilent's Q1 adjusted EPS of $1.36 fell short of Wall Street expectations of $1.37, causing shares to close down more than 3% in the following trading session.
- Only four out of 16 analysts covering the stock rate it as 'Hold', suggesting a lack of universal confidence compared to the dominant bullish sentiment.
Labcorp has announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, a US FDA-approved companion diagnostic designed to identify patients with platinum-resistant ovarian cancer who may be eligible for Merck's Keytruda. This diagnostic tool is significant because it is the only one currently approved by the US Food and Drug Administration specifically for this purpose within the context of ovarian cancer treatment. The availability allows clinicians to quickly and accurately pinpoint patients who can benefit from these targeted therapies, addressing a critical gap in care where approximately 80% of individuals with ovarian cancer experience recurrence after initial therapy, often developing resistance to platinum-based chemotherapy with limited options remaining.
Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) represent the first FDA-approved PD-1 inhibitors available as part of a complete treatment regimen for eligible patients with platinum-resistant ovarian cancer. Clinical findings indicate that these treatments reduce the risk of disease progression and improve overall survival, offering new hope for a challenging form of cancer that is currently incurable and offers limited benefits with current options. Following the FDA's approval in February, which included Keytruda, Keytruda Qlex, and the PD-L1 IHC 22C3 pharmDx diagnostic, Labcorp participated in Agilent Technologies' Early Validation Programme to ensure rapid testing readiness through standardized training and other preparatory activities.
Dr. Marcia Eisenberg, Ph.D., chief scientific officer at Labcorp, emphasized the critical nature of this development by stating that platinum-resistant ovarian cancer remains incurable with existing treatments providing only short-lived benefits, making it one of the most difficult conditions to manage. She noted that by making the companion diagnostic available nationwide, Labcorp is helping clinicians rapidly identify eligible patients and connect them with a therapy that offers new hope. Labcorp, described as a global leader in innovative and comprehensive laboratory services, aims to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions, advancing science to improve health and lives through its unparalleled diagnostics and drug development capabilities. This expansion follows the February regulatory approval, positioning the company to immediately support broader access to these life-extending treatments across the United States.
🔬 FDA-approved test enables identification of platinum-resistant ovarian cancer patients nationwide.
💊 Eligibility for Keytruda and Keytruda Qlex is confirmed via the new diagnostic.
⏳ 80% recurrence rates previously left limited treatment options for struggling patients.
📉 Therapy approval reduces disease progression risk and improves overall survival outcomes.
🔬 Labcorp has announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, a new companion diagnostic test for ovarian cancer patients.
✅ This is the only FDA-approved test specifically designed to identify patients with platinum-resistant ovarian cancer who may be eligible for treatment.
💊 The test supports access to Keytruda and Keytruda Qlex, which are the first FDA-approved PD-1 inhibitors authorized as a complete treatment regimen for this condition.
📉 Approximately 80% of individuals with ovarian cancer experience recurrence after initial therapy, often developing resistance to platinum-based chemotherapy.
⏳ Patients with platinum-resistant ovarian cancer previously faced limited treatment options and poor survival outcomes due to the incurable nature of the disease.
💡 Clinical approval for these therapies has been found to reduce the risk of disease progression and improve overall survival rates for eligible patients.
🤝 Labcorp's chief scientific officer, Dr. Marcia Eisenberg, stated that the diagnostic helps clinicians connect struggling patients with therapies offering new hope.
📜 The FDA approved Keytruda, Keytruda Qlex, and the companion diagnostic in February of this year following regulatory review.
🏭 Prior to nationwide launch, Labcorp participated in Agilent Technologies' Early Validation Programme to ensure rapid testing availability.
🎓 Through standardized training and readiness activities, Labcorp prepared its laboratories to expand access to the diagnostic quickly.
🌐 Labcorp is described as a global leader providing innovative laboratory services to doctors, hospitals, pharmaceutical companies, researchers, and patients.
🏥 The company's mission includes helping medical professionals make confident decisions and advancing science through diagnostics and drug development capabilities.
Bullish Signals
- Labcorp has introduced the only US FDA-approved companion diagnostic, Agilent Technologies' PD-L1 IHC 22C3 pharmDx, for identifying patients with platinum-resistant ovarian cancer eligible for Keytruda.
- The partnership enables clinicians to quickly identify patients who may benefit from newly approved treatments, reducing risk of disease progression and improving overall survival.
- Labcorp participated in Agilent Technologies' Early Validation Programme to support rapid testing availability nationwide following the FDA's February approval.
- This launch expands nationwide access to a therapy offering new hope for individuals with platinum-resistant ovarian cancer who previously had limited treatment options.
Risk Factors
- Approximately 80% of individuals with ovarian cancer experience recurrence after initial therapy, highlighting the severe unmet medical need despite new diagnostic approvals.
- The disease is incurable, and current treatment options offer limited and short-lived benefits for patients suffering from platinum-resistant ovarian cancer.
- Many patients develop resistance to platinum-based chemotherapy, leading to a critical lack of viable treatment options before these new therapies become accessible.
Agilent Technologies (NYSE:A) has entered into an agreement to acquire privately held Biocare Medical in an all-cash transaction valued at $950 million. The acquisition is designed to strengthen Agilent's position within cancer diagnostics and laboratory technologies, with Biocare set to integrate into Agilent's Life Sciences and Diagnostics Markets Group. Company Chief Executive Officer Padraig McDonnell stated that the deal aims to accelerate innovation while supporting long-term value creation for shareholders. According to a company statement reviewed by Bloomberg News, the transaction is expected to become accretive to earnings per share approximately 12 months after closing.
Biocare Medical, headquartered in the San Francisco Bay Area, specializes in instruments and materials used in cancer research, having generated more than $90 million in revenue in 2025. The company's portfolio includes over 300 specialized antibodies, reagents, and laboratory instruments utilized in both research and clinical environments. The deal is being executed by an investor group led by Excellere Partners and GHO Capital Partners, with financial advice from Jefferies Financial Group and legal counsel from Ropes & Gray, while Agilent retained Barclays and Sullivan & Cromwell for advisory and legal support respectively. This transaction represents Agilent's largest acquisition since the $1.17 billion purchase of BioTek Instruments in 2019, following the $925 million acquisition of Biovectra in 2024.
The strategic rationale for the acquisition includes expanding Agilent's analytical and clinical technologies portfolio by combining its existing capabilities with Biocare's offerings in antibodies, reagents, and instruments, potentially allowing the company to serve a broader set of laboratories. The deal is projected to close by the end of Agilent's fiscal fourth quarter, which concludes on October 31. Despite the acquisition activity, Agilent shares have declined approximately 15% this year, leaving the company with a market value of roughly $32.5 billion.
💰 Acquiring Biocare Medical for $950M all-cash deal targeting cancer diagnostics expansion.
📅 Expected to close by end of Q4 fiscal year (Oct 31).
🏆 Agilent's largest purchase since 2019 BioTek acquisition at $1.17B.
📈 Agilent Technologies agreed to acquire privately held Biocare Medical for $950 million in an all-cash deal.
🎯 The acquisition aims to strengthen Agilent's position in cancer diagnostics and laboratory technologies.
📊 Biocare, based in the San Francisco Bay Area, generated over $90 million in revenue in 2025.
🔬 Biocare develops specialized instruments, antibodies, and reagents for both research and clinical settings.
🤝 The transaction will integrate Biocare into Agilent's Life Sciences and Diagnostics Markets Group.
💸 Management expects the deal to become accretive to earnings per share approximately 12 months after closing.
⏰ CEO Padraig McDonnell stated the acquisition will accelerate innovation and support long-term shareholder value.
🧾 Biocare is being sold by an investor group led by Excellere Partners and GHO Capital Partners.
⚖️ Financial adviser Jefferies Financial Group and legal adviser Ropes & Gray represented the sellers in the deal.
🏦 Agilent was advised by Barclays and Sullivan & Cromwell for this transaction.
🔗 Combining portfolios could expand Agilent's capabilities to serve a broader range of laboratories.
📅 The acquisition is expected to close by the end of Agilent's fiscal fourth quarter, ending Oct. 31.
🏆 This marks Agilent's largest acquisition since its 2019 purchase of BioTek Instruments for $1.17 billion.
📉 Agilent shares have fallen about 15% this year with a current market value of roughly $32.5 billion.
Bullish Signals
- Agilent to acquire Biocare Medical for $950M all-cash.
- Deal strengthens cancer diagnostics and lab tech position.
- Expected EPS accretion within 12 months of closing.
- CEO McDonnell notes innovation acceleration and shareholder value.
- Biocare generated over $90M revenue in 2025 with 300+ antibodies.
- Expands Agilent portfolio by combining lab and clinical tech capabilities.
- Transaction expected to close end of Q4 on Oct. 31.
- Largest deal since 2019 BioTek purchase ($1.17B).
- Follows 2024 Biovectra acquisition ($925M), showing aggressive growth.
Risk Factors
- Agilent buys Biocare for $950M cash, impacting liquidity
- GuruFocus flags 2 warning signs on valuation/health
- Shares down 15% this year despite deal
- Largest acquisition since 2019 BioTek for $1.17B
- Aggressive growth spending may hurt near-term earnings
- EPS accretive only after 12 months post-closing
- All-cash deal increases leverage and cash burn
Bullish Signals
- Agilent Technologies agreed to acquire privately held Biocare Medical in an all-cash deal valued at $950 million, strengthening its position in cancer diagnostics and laboratory technologies.
- The transaction is expected to become accretive to earnings per share roughly 12 months after closing, signaling financial benefits for shareholders.
- CEO Padraig McDonnell stated the acquisition will accelerate innovation while supporting long-term value creation for shareholders.
- Biocare generated more than $90 million in revenue in 2025 and offers more than 300 specialized antibodies alongside a range of reagents and laboratory instruments.
- The deal expands Agilent's analytical and clinical technologies portfolio by combining its capabilities with Biocare's antibody, reagent and instrument offerings to serve a broader set of laboratories.
- The transaction is expected to close by the end of Agilent's fiscal fourth quarter ending Oct. 31.
- This acquisition represents the company's largest acquisition since its $1.17 billion purchase of BioTek Instruments in 2019 and follows the $925 million acquisition of Biovectra in 2024, indicating an aggressive growth strategy.
- Agilent Technologies agreed to acquire privately held Biocare Medical in an all-cash deal valued at $950 million, strengthening its position in cancer diagnostics and laboratory technologies.
- The transaction is expected to become accretive to earnings per share roughly 12 months after closing, signaling financial benefits for shareholders.
- CEO Padraig McDonnell stated the acquisition will accelerate innovation while supporting long-term value creation for shareholders.
- Biocare generated more than $90 million in revenue in 2025 and offers more than 300 specialized antibodies alongside a range of reagents and laboratory instruments.
- The deal expands Agilent's analytical and clinical technologies portfolio by combining its capabilities with Biocare's antibody, reagent and instrument offerings to serve a broader set of laboratories.
- The transaction is expected to close by the end of Agilent's fiscal fourth quarter ending Oct. 31.
- This acquisition represents the company's largest acquisition since its $1.17 billion purchase of BioTek Instruments in 2019 and follows the $925 million acquisition of Biovectra in 2024, indicating an aggressive growth strategy.
Risk Factors
- Agilent Technologies has agreed to acquire Biocare Medical for $950 million in all-cash, which represents a significant capital outlay that could impact liquidity.
- The article warns that GuruFocus detected 2 Warning Signs associated with UBS regarding the company's valuation or financial health.
- Shares have fallen about 15% this year despite the acquisition announcement, indicating potential market skepticism or broader sector concerns.
- This is Agilent's largest acquisition since its $1.17 billion purchase of BioTek Instruments in 2019 and follows a $925 million acquisition of Biovectra in 2024, suggesting aggressive growth spending that may affect near-term earnings.
- Integration of Biocare into the Life Sciences and Diagnostics Markets Group will not become accretive to earnings per share until roughly 12 months after closing, delaying financial benefits.
- Acquisition costs will be paid in all-cash, increasing leverage or cash burn without immediate revenue recognition from the deal.
On February 25, Students for Justice in Palestine (SJP) protested at the University of Vermont's Spring Job and Internship Fair, calling on students to boycott five specific companies they claim manufacture technology used by the Israeli military. The protest took place from 11 a.m. to 3 p.m. outside the Davis Center’s third-floor entrance, where organizers distributed pamphlets titled "Arms Off Campus" and carried Palestinian flags alongside signs reading "No killers @ UVM" and "Engineering students: you don't have to work for RTX." According to SJP's Instagram post, the five targeted organizations are General Dynamics, Agilent Technologies, Global Foundries, RTX Corporation, and Marvell Technology.
Only two of the five companies, Agilent Technologies and Marvell Technologies, were present at Wednesday’s career fair, though SJP continues to oppose all five firms' presence at UVM's 2025 Fall Job and Internship Fair and the 2025 Engineering and Technology Fair. Junior Joe Murphy, a protest organizer, stated that hosting these companies makes the university complicit in the genocide in Gaza and argued that SJP had not been directed to staff with actual decision-making power regarding the employer list. Senior Sky Mandel emphasized the importance of informing the student body about the connections between these corporations and the Israel-Palestine conflict, urging students to divest from weapons manufacturing and put pressure on university administration for policy changes.
Graduate student Ayana Curran-House of the Palestine Solidarity Caucus attended the rally to support SJP’s efforts, expressing disappointment that the university continues to bring employers she believes are facilitating injustice. Outside the main entrance, protesters held a banner demanding "Arms Off Campus," with Murphy speaking through a megaphone about global violence and the responsibility to stand against such corporations. The group plans to continue speaking out whenever these companies are brought to campus, highlighting their demand for UVM to take a definitive stance against the weapons manufacturers involved in the Israel-Palestine conflict.
✊ SJP protested Feb 25 urging students to avoid five companies linked to Israel's military tech.
🚫 Agilent and Marvell were present; others targeted include General Dynamics, RTX, Global Foundries.
📣 Demands divest from weapons manufacturing with "Arms Off Campus" pamphlets distributed at event.
🕊️ UVM Students for Justice in Palestine (SJP) protested at the campus job fair on Feb. 25 from 11 a.m. to 3 p.m.
✋ The group urged students to abstain from networking with five specific companies alleged to supply technology for the Israeli military.
🚫 The targeted employers include General Dynamics, Agilent Technologies, Global Foundries, RTX Corporation, and Marvell Technology.
📣 Protesters distributed pamphlets titled "Arms Off Campus" and carried signs demanding an end to weapons manufacturing on campus.
💼 Only two of the five protested companies, Agilent Technologies and Marvell Technologies, were actually present at the fair.
⚠️ SJP organizers claim UVM hosts these firms because they are complicit in the genocide in Gaza.
🗣️ Junior Joe Murphy stated that protesting is necessary because administration staff lack the power to change company listings effectively.
📢 Graduate student Ayana Curran-House criticized the university for bringing in employers she views as contributing to injustice.
🔍 All five companies are accused by SJP of supplying Israel with technology used for weaponry and surveillance.
⏸️ Similar protests were held at previous UVM job fairs in 2025 targeting the same corporate list.
💬 Organizer Sky Mandel emphasized the need to pressure the administration to divest from weapons manufacturing entirely.
🚩 Protesters displayed Palestinian flags and gathered outside the Davis Center with messages like "No killers @ UVM."
🌍 The group linked global violence, including ICE actions, to the failure to stop the genocide in Gaza.
Bullish Signals
- Five tech companies (General Dynamics, Agilent, Global Foundries, RTX, Marvell) held career fair.
- Agilent Technologies and Marvell Technologies engaged at Wednesday's fair.
- SJP organizer Sky Mandel distributed pamphlets in Davis Center.
- Students viewed 'UVM Students Demand Arms Off Campus' protest banner.
- Student leaders Joe Murphy and Ayana Curran-House organize campus events.
Bullish Signals
- Five technology companies (General Dynamics, Agilent Technologies, Global Foundries, RTX Corporation, Marvell Technology) participated in the Spring Job and Internship Fair, presenting career opportunities for students.
- Agilent Technologies and Marvell Technologies were present at Wednesday's career fair to engage with prospective employees.
- SJP organizer Sky Mandel distributed pamphlets inside the Davis Center to inform students about employer participation, facilitating open dialogue.
- The SJP protest included a banner reading 'UVM Students Demand Arms Off Campus,' encouraging student awareness and engagement.
- Student leaders like Junior Joe Murphy and Graduate student Ayana Curran-House are actively organizing community events to foster discussion on campus employment values.
The article provides a dividend analysis for Agilent Technologies (ticker A) covering the first quarter of 2026, outlining both bullish and bearish perspectives on the stock. Specifically regarding cash flow and dividend sustainability, the text notes that the current dividend represents only 41% of operating free cash flow. This ratio is influenced by several one-time factors that impacted net income and cash flow in the period; notably, a cash flow decline was driven by one-time tax and incentive payments totaling $255 million. While net income saw a growth of 3%, cash flow was negatively affected by $150 million in employee compensation payments, $105 million in taxes, and a five-day increase in Days Sales Outstanding metrics.
Looking ahead to obligations due in September 2026, the article indicates that roughly $304 million is required, which is well-covered by current cash and marketable securities totaling $1.8 billion. The company is currently prioritizing an $1.8 billion share repurchase program alongside significant capital expenditures aimed at expanding its nucleic acid therapeutics manufacturing in Colorado. For shareholders, the specific dividend payout detailed is $0.255 per share, scheduled to be payable on April 22, 2026. The analysis also contextualizes Agilent within broader investment discussions by comparing its financial structure against other popular stocks like Uber and Duolingo, though noting that investors sometimes overlook critical details such as profit concentration in specific metro markets or accounting nuances.
The content emphasizes a cautious approach to financial information, highlighting that the text is powered by AI and rarely involves an editor, which may lead to unintentional errors, especially with numerical data. It explicitly states that the analysis serves as a starting point for independent research rather than a financial recommendation or advice. The authors warn that investing is risky and forward-looking statements regarding analysis may be incorrect, urging readers to verify all information independently. Additionally, there are disclosures regarding conflicts of interest where the firm may hold changing financial positions, with such conflicts disclosed in specific articles.
💰 Dividend of $0.255/share approved, payable April 2026 (approx. $304M total obligation).
📉 Cash flow hit by $255M one-time payments and 5-day DSO increase despite modest 3% net income growth.
🔄 Company prioritizes $1.8B share repurchase program while expanding Colorado nucleic acid manufacturing.
🔬 Agilent's dividend represents 41% of its operating free cash flow for the quarter.
💸 Cash flow was negatively impacted by $255 million in one-time tax and incentive payments.
📉 Specific cash flow drag included $150 million in employee compensation and $105 million in taxes.
⏱️ Days Sales Outstanding increased by 5 days, further contributing to reduced cash flow.
📅 Approximately $304 million of dividends is due for payment in September 2026.
💰 Current cash and marketable securities total $1.8 billion, covering the upcoming dividend obligation.
🔄 Management prioritizes a $1.8 billion share repurchase program alongside capital expenditures.
🏗️ Capital expenditures are directed toward nucleic acid therapeutics manufacturing expansion in Colorado.
💸 The upcoming quarterly dividend is set at $0.255 per share, payable on April 22, 2026.
📈 Net income for the period showed a modest growth of 3%.
⚖️ Analysis covers both bull and bear cases to help investors identify market biases and overlooked risks.
📝 The content notes it is AI-powered and may contain unintentional errors or omissions regarding specific figures.
⚠️ Investors are advised that the analysis is not financial advice and should verify all information independently.
Bullish Signals
- Dividend yield of $0.255/share is just 41% of FCF.
- $1.8B cash covers $304M Sept 2026 debt obligations.
Risk Factors
- Free cash flow declining; dividend covers only 41% of payouts
- $150M compensation, $105M taxes, and higher DSO hurt cash flow
- $1.8B buyback plus CapEx could strain liquidity amid cash declines
- $304M payment due Sept 2026 requires careful cash management
- Analysis disclaimer warns of potential errors in financial numbers
Bullish Signals
- The dividend payout of $0.255 per share represents only 41% of operating free cash flow, indicating sufficient financial strength to maintain or potentially increase payouts in the future.
- Agilent has robust liquidity with $1.8 billion in current cash and marketable securities, which is well-positioned to cover the approximately $304 million due in September 2026.
Risk Factors
- Operating free cash flow is declining, with the dividend representing only 41% of this metric, indicating potential stress in generating sufficient cash to sustain payouts.
- Cash flow was dragged down by $150 million in employee compensation payments, $105 million in taxes, and a 5-day increase in Days Sales Outstanding, highlighting inefficiencies and rising costs.
- Agilent is prioritizing an $1.8 billion share repurchase program alongside significant capital expenditures for manufacturing expansion, which could strain liquidity given the recent cash flow declines.
- A substantial $304 million payment is due in September 2026, creating a near-term capital demand that requires careful management of current cash and marketable securities.
- The content disclaimer notes that the analysis may contain unintentional errors and omissions, especially with numbers, reducing confidence in the specific financial projections provided.
A group of ten research tools and consumables stocks reported Q4 earnings that collectively beat analysts' consensus revenue estimates by 1.2%, though next quarter's guidance remained in line with expectations. Despite the positive financial results, investor sentiment has been tepid, with the average share price of these companies down 19.5% since the latest reporting period. The sector remains subject to ongoing challenges including high R&D costs, pricing pressures from budget-conscious institutions, and sensitivity to macroeconomic conditions affecting research funding cycles.
Among the specific performers, Agilent Technologies (NYSE:A) delivered the weakest performance against analyst estimates within the tracked group, with revenues of $1.80 billion rising 7% year on year but failing to beat expectations for next quarter's revenue. The stock has declined 9.4% since reporting and trades at $112.94. Bio-Techne (NASDAQ:TECH) saw revenues flat year on year at $295.9 million, which was an organic revenue beat of 2%, though its shares fell 18.4% to $52.72. Conversely, Mettler-Toledo (NYSE:MTD) reported revenues of $1.13 billion up 8.1%, exceeding expectations by 2.3%, but significantly missed next quarter's revenue and EPS guidance estimates, leading to a 12.9% stock decline from $1,204.
Revvity (formerly PerkinElmer) posted revenues of $772.1 million, up 5.8% year on year, surpassing expectations by 1.1% and posting the weakest full-year guidance update among its peers despite beating organic revenue estimates; its stock is down 18.3% to $88.86. Sotera Health Company (NASDAQGS:SHC) achieved a significant beat of 1.2% with revenues of $303.4 million up 4.6% year on year, also pulling off the highest full-year guidance raise among peers, though shares are down 22.8% to $13.50. The article concludes by noting that while AI presents headwinds such as eroding pricing power for software companies, it simultaneously opens new opportunities in laboratories through automation and AI-driven solutions for selling tools and consumables.
📈 Sector Q4 revenues beat consensus by 1.2%, though average shares are down 19.5% post-earnings
⚖️ Top performers include Sotera Health (guidance raise) and Mettler-Toledo (strong growth), offsetting Agilent's weakness
🔍 Key risks involve supply chain disruptions and macro headwinds, with AI-driven solutions driving future demand
🔬 The research tools & consumables subsector supports scientific discoveries across academia, biotech, and pharma through essential laboratory products.
📈 As a group, 10 tracked companies reported satisfactory Q4 results with revenues beating analyst consensus estimates by 1.2%.
⚠️ Despite positive earnings news, the sector's average share prices are down 19.5% since the latest earnings reports.
🧬 Agilent (NYSE:A) reported $1.80 billion in Q4 revenue, up 7% year-on-year but delivering the weakest performance within the tracked group.
💸 Agilent’s stock is down 9.4% since reporting and trades at $112.94 with next-quarter revenue guidance beating expectations.
🧪 Bio-Techne (NASDAQ:TECH) reported flat year-on-year revenues of $295.9 million, outperforming analyst organic revenue estimates by 2%.
📉 Bio-Techne’s stock has fallen 18.4% since reporting and currently trades at $52.72 despite a solid operational quarter.
⚖️ Mettler-Toledo (NYSE:MTD) achieved 8.1% year-on-year revenue growth to $1.13 billion, exceeding analyst expectations by 2.3%.
📉 Mettler-Toledo missed next-quarter revenue and EPS guidance significantly, with its stock down 12.9% since results reporting.
🧬 Revvity (NYSE:RVTY) reported $772.1 million in Q4 revenue, a 5.8% increase that surpassed analyst expectations by 1.1%.
🔍 Revvity provided the weakest full-year guidance update among peers with its stock down 18.3% to $88.86 post-earnings.
🛡️ Sotera Health Company (NASDAQGS:SHC) generated $303.4 million in revenue, up 4.6%, and beat analyst full-year EPS guidance significantly.
🚀 Sotera Health recorded the highest full-year guidance raise among peers with its stock trading at $13.50 after a 22.8% decline.
⏳ The sector faces headwinds including supply chain disruptions, macroeconomic sensitivity, and pricing pressures from budget-conscious institutions.
🤖 Future growth is expected from demand in synthetic biology, personalized medicine, and the rise of AI-driven laboratory solutions.
Bullish Signals
- Research tools & consumables subsector revenues beat analyst consensus by 1.2%
- Ag Technologies reported YoY revenue growth of 7% to $1.80B
- Bio-Techne beat analyst expectations by 2% with $295.9M in revenues
- Mettler-Toledo achieved YoY revenue growth of 8.1% to $1.13B
- Revvity posted 5.8% YoY revenue growth and topped analyst expectations
- Revvity full-year revenue guidance slightly exceeded analyst expectations
- Sotera Health beat EPS guidance estimates and topped revenue expectations
- Sotera Health raised full-year guidance highest among peers
Risk Factors
- Research tools face R&D pressure, pricing headwinds, and funding volatility.
- Shares averaged a 19.5% decline since Q4 earnings.
- Agilent stock down 9.4% despite in-line revenue due to weak estimates beat.
- Mettler-Toledo stock fell 12.9% after missing next quarter guidance.
- Revvity stock dropped 18.3% on weakest full-year guidance among peers.
- Sotera Health shares down 22.8% despite beating EPS and revenue estimates.
- Bio-Techne stock fell 18.4% as market unhappy with flat revenue growth.
Bullish Signals
- The research tools & consumables subsector delivered a satisfactory Q4 with group revenues beating analysts' consensus estimates by 1.2%.
- Agilent Technologies reported year-over-year revenue growth of 7% to $1.80 billion, meeting analyst expectations.
- Bio-Techne outperformed analysts' expectations by 2% with revenues of $295.9 million and a solid beat on organic revenue estimates.
- Mettler-Toledo reported year-over-year revenue growth of 8.1% to $1.13 billion, exceeding analysts' expectations by 2.3%.
- Revvity achieved strong performance with revenues up 5.8% year over year and surpassed analysts' expectations by 1.1%.
- Revvity logged full-year revenue guidance slightly topping analysts' expectations and beat organic revenue estimates.
- Sotera Health Company produced an impressive beat of analysts' full-year EPS guidance estimates and topped revenue expectations.
- Sotera Health Company pulled off the highest full-year guidance raise among its peers, signaling strong future outlook.
Risk Factors
- The research tools subsector faces significant headwinds including high R&D investment requirements to maintain technological leadership, pricing pressures from budget-conscious institutions, and vulnerability to fluctuations in research funding cycles.
- Amidst satisfactory Q4 earnings results for the group, share prices have had a rough stretch with the average decline of 19.5% since latest earnings results.
- Agilent Technologies delivered the weakest performance against analyst estimates of the whole group despite revenue being in line with expectations, leading to its stock down 9.4%.
- Mettler-Toledo posted significant misses for next quarter's revenue guidance and EPS guidance estimates which caused its stock to fall 12.9% since reporting.
- Revvity had the weakest full-year guidance update among its peers despite a strong quarterly performance, resulting in its stock down 18.3%.
- Sotera Health Company saw its stock drop 22.8% from reporting results, indicating market concern despite beating analyst expectations on EPS and revenue guidance.
- Bio-Techne's flat year-on-year revenue growth outperformed expectations slightly but the market remains unhappy as the stock is down 18.4% since reporting.
The provided text appears to be a collection of Zacks.com articles and informational pages rather than a single news article about Agilent Technologies. The content primarily details Zacks' proprietary rating systems, including the short-term and long-term "Zacks Rank," which grades stocks into five categories from A (best) to F (worst). It explains that investors should target companies with a Zacks Rank of #1 or #2 and an 'A' or 'B' style score. The text also describes the "Zacks Industry Rank," which categorizes 265 X Industries based on their average performance, with the top industry placing in the top 1% and the worst in the bottom 1%.
Specific information regarding Agilent Technologies (stock symbol A) indicates that the company is a Santa Clara, CA-based manufacturer spun off from Hewlett-Packard. It operates three business segments: Life Sciences & Applied Markets Group (LSAG), Diagnostics and Genomics Group (DGG), and Agilent Cross Lab Group (ACG). The text notes that Agilent uses a direct sales model supplemented by distributors and resellers. Regarding financial performance, an article from February 24, 2026, states that for the quarter ended January 2026, Agilent reported earnings surprises of -0.52% and revenue surprises of -0.27%, resulting in shares dropping in pre-market trading due to margin pressure and a missed earnings target despite positive revenue growth.
The text also includes snippets from February 26, 2026, which suggest that while top-and-bottom-line numbers provide a sense of quarterly performance for the quarter ended January 2026, investors should also examine key metrics against Wall Street estimates and year-ago values to understand future prospects. Other entries discuss comparable companies like Bio-Rad (BIO) and ResMed (RMD), providing their specific earnings surprises for the quarter ended December 2025, though these do not constitute a summary of Agilent's overall news but rather context within Zacks' research ecosystem. The date on the primary update indicates this information was last refreshed on March 27, 2026.
📊 Agilent is a test and measurement OEM serving Life Sciences, Diagnostics, and Cross Lab markets.
📉 Q1 earnings missed estimates with margins pressured by margin issues.
📉 Stock traded lower on earnings miss reported in late February.
📊 Agilent Technologies (A) is a Santa Clara-based OEM specializing in test and measurement products across Life Sciences, Diagnostics, and Cross Lab segments.
🏭 The company originated as a spin-off from Hewlett-Packard and primarily uses a direct sales model supplemented by distributors and electronic commerce.
📉 For the quarter ended January 2026, Agilent reported earnings and revenue surprises of -0.52% and -0.27%, respectively, falling short of estimates.
💹 Shares traded lower in pre-market trading following the margin pressure and earnings miss announced on February 24, 2026.
📅 Zacks Equity Research published an analysis on March 27, 2026, evaluating Agilent's stock outlook following the recent 30-day-old earnings report.
📈 Investors are encouraged to use Zacks Earnings ESP tools and evaluate reliance on international revenue for financial stability insights.
🧬 The company serves multiple end markets with a broad portfolio including its LSAG, DGG, and ACG business segments.
⚠️ While top- and bottom-line numbers provide quarterly performance context, analysts recommend examining key metric estimates versus Wall Street expectations.
🔗 Zacks Rank Education and Style Scores resources are available for investors seeking to understand timeliness indicators and trading style fits.
🏆 Agilent currently holds a Zacks Industry Rank within the Medical - Products industry (Bottom 35% of 243 ranked industries).
Bullish Signals
- Broad OEM portfolio serving multiple end markets.
- Three business segments: LSAG, DGG, ACG.
- Direct sales plus distributors, resellers, e-commerce.
Risk Factors
- Negative earnings surprise of -0.52% and revenue miss
- Shares lower on margin pressure despite revenue beat
- Industry rank at Bottom 35%, C VGM Style
Bullish Signals
- Agilent Technologies (A) is an original equipment manufacturer (OEM) with a broad-based portfolio of test and measurement products serving multiple end markets.
- The company has three distinct business segments: Life Sciences & Applied Markets Group (LSAG), Diagnostics and Genomics Group (DGG), and Agilent Cross Lab Group (ACG).
- Agilent uses a direct sales model supplemented by distributors, resellers, manufacturers' representatives, telesales, and electronic commerce to distribute its products.
Risk Factors
- Agilent reported negative earnings surprise of -0.52% and revenue surprise of -0.27% for the quarter ended January 2026, falling below Wall Street estimates.
- Shares traded lower in pre-market despite revenue beat due to margin pressure and earnings miss, indicating investor concern over profitability.
- Industry Rank is at the Bottom 35% (159 out of 243) with only a C VGM Style Score, suggesting weaker relative performance compared to peers.
